

# Press Release

## ProStrakan Group plc

### Director / PDMR Shareholding

ProStrakan Group plc (the "Company") has today received notification that on 4 May 2010, a total of 450,247 ordinary shares in the Company ("Shares") were acquired by the following Executive Director and other Persons Discharging Managerial Responsibilities ("PDMRs") on the exercise of awards granted under the ProStrakan Group Performance Share Plan 2005 (the "Plan"):

Name	Role	Number of Shares acquired on exercise
Wilson Totten	Executive Director	209,252
Nigel Atherton	PDMR	66,173
Abid Karim	PDMR	62,596
Andrew McLean	PDMR	60,808
Thomas Stratford	PDMR	51,418

The above awards (which were in the form of options with a nil exercise price) were originally granted under the Plan on 25 April 2007 and became exercisable on 4 May 2010.

The Company has also received notification that, in order to account for the tax payable on the above exercises, a total of 234,629 Shares were sold on 14 May 2010 at a price of 79.9 pence per Share on behalf of the relevant Executive Director and other PDMRs. In addition, Andrew McLean sold a further 5,000 Shares on 14 May 2010 at a price of 79.9 pence per Share.

Following the above notifications, the relevant Executive Director and other PDMRs, together with their connected parties, have the following interests in the share capital of the Company:

Name	Role	Total holding following this notification	Approximate % of Company's issued share capital
Wilson Totten	Executive Director	630,817	0.31
Nigel Atherton	PDMR	69,848	0.03
Abid Karim	PDMR	56,290	0.02
Andrew McLean	PDMR	40,119	0.02
Thomas Stratford	PDMR	164,620	0.08

The above notifications are intended to satisfy the Company's obligations under Disclosure and Transparency Rule 3.1.4R.

Andrew McLean  
Company Secretary

**Further enquiries:**

Callum Spreng  
Corporate Communications  
ProStrakan

01896 664000

Jon Coles/Justine McIlroy  
Brunswick Group

020 7404 5959

**About ProStrakan:**

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels, UK, and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

Further information about the business can be found at: [www.prostrakan.com](http://www.prostrakan.com)